As all professional societies recommend in their guidelines, patients with chronic HBV should receive antiviral prophylaxis when they start non-TNF-targeted biologics. In patients with resolved HBV, the rates of HBV reactivation without antiviral prophylaxis in patients receiving IL-23, IL-17, and JAK inhibitors were up to 2.3%, 4.2%, and 0%, respectively.